Corbus Pharma

Corbus Pharma Corbus (Nasdaq: CRBP) is connecting innovation to purpose to improve the futures of cancer and obesity patients.

08/26/2026

Incretin therapies like tirzepatide and semaglutide have transformed care, but urgent unmet clinical needs remain. Early research on CRB-913 indicates it may significantly amplify the effectiveness of these transformative therapies, potentially providing sustained weight loss without excessive loss of muscle mass or unwanted neuropsychiatric effects. Learn more about CRB-913's potential: https://bit.ly/40Lts1n

08/20/2026

What is CRB-913? It's a next-generation, daily CB1 inverse agonist in development for the treatment of . CRB-913 is designed to act on peripheral CB1 receptors without affecting those in the central nervous system, with the goal of reducing food intake and promoting weight loss while minimizing CNS side effects. Learn more about the science behind CRB-913: https://bit.ly/40Lts1n

08/06/2026

Our CEO, Yuval Cohen, Ph.D. comments on the potential of CRB-701 in oropharyngeal cancer and CRB-913 in obesity, highlighting two potentially impactful clinical development milestones anticipated in September. Read more for Q2 2026 key corporate and program updates: https://bit.ly/3RNjk7J

08/06/2026

Corbus today provided a corporate update and reported financial results for the 2026 second quarter ended June 30, 2026. For details: https://bit.ly/3RNjk7J

08/04/2026

“Despite the remarkable success of GLP-1s and the incretin class, significant treatment gaps exist for people struggling with obesity,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. Learn about Corbus’ CANYON-1 study of CRB-913 for the treatment of obesity: https://bit.ly/4fLoHfr

08/04/2026

Corbus today announced the last patient has completed their last clinical visit (“Last Patient Last Visit”) in the Company’s CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The CANYON-1 study is on track for topline data readout in September 2026. Learn more: https://bit.ly/4fLoHfr

07/31/2026

At Corbus, we are developing CRB-913, a next-generation daily oral medication designed to selectively target the cannabinoid receptor type 1 (CB1) to treat more safely and effectively. Learn more: https://bit.ly/40Lts1n

07/29/2026

TEMPO-1 is a randomized controlled study (n=250) designed to evaluate the efficacy and safety of CRB-701 compared with investigator’s choice of capecitabine, cetuximab or docetaxel. The study's primary endpoint is objective response rate (ORR), which is intended to support a potential accelerated approval; overall survival (OS) is intended to support potential conversion to full approval. Learn more: https://bit.ly/4fzBcw1

07/28/2026

Our CEO, Yuval Cohen, Ph.D., comments on the potential of CRB-701 as a treatment option for patients with 2L oropharyngeal cancer, a distinct tumor-type that is on the rise due to HPV infections. Read about the TEMPO-1 registrational study: https://bit.ly/4fzBcw1

07/28/2026

Corbus today announced that the U.S. FDA has cleared the start of the Company’s registrational study (“TEMPO-1”) of CRB-701, a next-generation Nectin-4 targeted antibody drug conjugate (ADC), in second-line (2L) oropharyngeal squamous cell carcinoma (OPSCC). For details: https://bit.ly/4fzBcw1

Address

500 River Ridge Drive, Second Floor
Norwood, MA
02062

Telephone

+16179630100

Website

Alerts

Be the first to know and let us send you an email when Corbus Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Corbus Pharma:

Shortcuts

Share

Category